Skip to main content
Year archive

Enlivex Therapeutics Ltd. — 2020 filings

All 78 regulatory filings released by Enlivex Therapeutics Ltd. (ENLV) in 2020, sourced directly from the official regulator.

78 Filings
2020 Period
2020 filings (78)
Filing Released Lang
Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on medRxiv
Regulatory Filings
2020-12-21 English
Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on medRxiv
Report Publication Announcement
2020-12-21 English
Issuance of New Chinese Patent Covering Allocetra Immunotherapy
Regulatory Filings
2020-12-07 English
Issuance of New Chinese Patent Covering Allocetra Immunotherapy
Report Publication Announcement
2020-12-07 English
Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra
Regulatory Filings
2020-11-18 English
Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra
Report Publication Announcement
2020-11-18 English
Appoints Former ArQule, Inc. Executive Dr. Brian Schwartz to the Company’s Board of Directors
Board/Management Information
2020-11-17 English
Appoints Former ArQule, Inc. Executive Dr. Brian Schwartz to the Company’s Board of Directors
Report Publication Announcement
2020-11-17 English
Enlivex to Present Schedule for Sepsis, COVID-19 and Solid Cancer Programs at H.C. Wainwright’s 6th Annual Israel Conference
Regulatory Filings
2020-11-12 English
Enlivex to Present Schedule for Sepsis, COVID-19 and Solid Cancer Programs at H.C. Wainwright’s 6th Annual Israel Conference
Report Publication Announcement
2020-11-12 English
Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, and Ulcerative Colitis with Allocetra Immunotherapy
Regulatory Filings
2020-11-05 English
Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, and Ulcerative Colitis with Allocetra Immunotherapy
Report Publication Announcement
2020-11-05 English
Israeli Ministry of Health Authorizes Initiation of Phase IIb Clinical Trial Evaluating Safety and Efficacy of Allocetra in Sepsis Patients
Regulatory Filings
2020-11-03 English
Israeli Ministry of Health Authorizes Initiation of Phase IIb Clinical Trial Evaluating Safety and Efficacy of Allocetra in Sepsis Patients
Report Publication Announcement
2020-11-03 English
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2020
Interim / Quarterly Report 9M 2020
2020-10-30 English
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2020
Report Publication Announcement
2020-10-30 English
will host a COVID-19 webinar on Thursday, November 5, 2020
Regulatory Filings
2020-10-27 English
will host a COVID-19 webinar on Thursday, November 5, 2020
Report Publication Announcement
2020-10-27 English
Reports Dosing of First Two Patients in Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
Regulatory Filings
2020-10-22 English
Reports Dosing of First Two Patients in Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
Report Publication Announcement
2020-10-22 English
K-6- Entered into an At The Market Offering agreement with with H.C. Wainwright
Regulatory Filings
2020-10-22 English
K-6- Entered into an At The Market Offering agreement with with H.C. Wainwright
Report Publication Announcement
2020-10-22 English
Prospectus Supplement
Capital/Financing Update
2020-10-22 English
Prospectus Supplement
Report Publication Announcement
2020-10-22 English
After Expedited Review, Israeli Ministry of Health Authorizes Initiation of Phase II Clinical Trial Evaluating Allocetra in COVID-19 Severe and Critical Patients
Regulatory Filings
2020-10-13 English
After Expedited Review, Israeli Ministry of Health Authorizes Initiation of Phase II Clinical Trial Evaluating Allocetra in COVID-19 Severe and Critical Patients
Report Publication Announcement
2020-10-13 English
Form 6-K/A- CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2020
Interim / Quarterly Report H1 2020
2020-10-13 English
Form 6-K/A- CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2020
Report Publication Announcement
2020-10-13 English
Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition
Regulatory Filings
2020-10-01 English
Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition
Report Publication Announcement
2020-10-01 English
FOLLOWING PUBLICATIONS TRADING IN THE COMPANY'S SHARES WAS HALTED
Regulatory Filings
2020-10-01 Hebrew (modern)
Enlivex Announces Allowance of New Chinese Patent Covering Allocetra Immunotherapy
Regulatory Filings
2020-09-16 English
Enlivex Announces Allowance of New Chinese Patent Covering Allocetra Immunotherapy
Report Publication Announcement
2020-09-16 English
Announces Allowance of New U.S. Patent Covering Allocetra Immunotherapy
Regulatory Filings
2020-08-25 English
Announces Allowance of New U.S. Patent Covering Allocetra Immunotherapy
Report Publication Announcement
2020-08-25 English
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTH PERIODS ENDED JUNE 30, 2020
Interim / Quarterly Report H1 2020
2020-08-15 English
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTH PERIODS ENDED JUNE 30, 2020
Report Publication Announcement
2020-08-15 English
The company's report was published abroad
Regulatory Filings
2020-08-10 Hebrew (modern)
Enlivex Announces Dosing of First Patient in Clinical Trial of Allocetra in COVID-19 Patients with Severe Illness Respiratory Failure
Regulatory Filings
2020-08-10 English
Enlivex Announces Dosing of First Patient in Clinical Trial of Allocetra in COVID-19 Patients with Severe Illness Respiratory Failure
Report Publication Announcement
2020-08-10 English
Enlivex held its 2020 Annual and Extraordinary General Meeting of Shareholders
Declaration of Voting Results & Voting Rights Announcements
2020-06-29 English
Enlivex held its 2020 Annual and Extraordinary General Meeting of Shareholders
Report Publication Announcement
2020-06-29 English
Enlivex Announces Allowance of New Japanese Patent Application Covering ALLOCETRA Immunotherapy
Regulatory Filings
2020-06-18 English
Enlivex Announces Allowance of New Japanese Patent Application Covering ALLOCETRA Immunotherapy
Report Publication Announcement
2020-06-18 English
Remote Access to Annual and Extraordinary General Meeting of Shareholders
AGM Information
2020-06-15 English
Remote Access to Annual and Extraordinary General Meeting of Shareholders
Report Publication Announcement
2020-06-15 English
Enlivex Presents New Clinical Data Demonstrating Early Resolution of Cytokine Storms in Sepsis Patients Treated with Allocetra at the International Society for Cellular Therapy 2020 Paris Virtual Ann
Regulatory Filings
2020-05-28 English
Enlivex Presents New Clinical Data Demonstrating Early Resolution of Cytokine Storms in Sepsis Patients Treated with Allocetra at the International Society for Cellular Therapy 2020 Paris Virtual Ann
Report Publication Announcement
2020-05-28 English
Annual and Extraordinary General Meeting of Shareholders
AGM Information
2020-05-19 English
Annual and Extraordinary General Meeting of Shareholders
AGM Information
2020-05-19 English
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2020
Interim / Quarterly Report Q1 2020
2020-05-19 English
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2020
Report Publication Announcement
2020-05-19 English
Enlivex Announces Initiation of Multi-Center Phase II Investigator-Initiated Clinical Trial of Allocetra in COVID-19 Patients
Regulatory Filings
2020-05-07 English
Enlivex Announces Initiation of Multi-Center Phase II Investigator-Initiated Clinical Trial of Allocetra in COVID-19 Patients
Report Publication Announcement
2020-05-07 English
20-F for 2019
Annual Report FY 2019
2020-05-01 English
20-F for 2019
Report Publication Announcement FY 2019
2020-05-01 English
Enlivex Selected by the Israel Innovation Authority to Receive $1.5 Million Grant to Fund COVID-19 and Sepsis Clinical Trials
Regulatory Filings
2020-04-13 English
Enlivex Selected by the Israel Innovation Authority to Receive $1.5 Million Grant to Fund COVID-19 and Sepsis Clinical Trials
Report Publication Announcement
2020-04-13 English
Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis
Regulatory Filings
2020-03-18 English
Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis
Report Publication Announcement
2020-03-18 English
6K: Enlivex Therapeutics Announces $16.75 Million Registered Direct Offering
Regulatory Filings
2020-03-05 English
6K: Enlivex Therapeutics Announces $16.75 Million Registered Direct Offering
Report Publication Announcement
2020-03-05 English
Prospectus Supplement to Prospectus dated June 21, 2019
Capital/Financing Update
2020-03-04 English
Prospectus Supplement to Prospectus dated June 21, 2019
Report Publication Announcement
2020-03-04 English
Enlivex Therapeutics Announces $16.75 Million Registered Direct Offering
Capital/Financing Update
2020-03-02 English
Enlivex Therapeutics Announces $16.75 Million Registered Direct Offering
Report Publication Announcement
2020-03-02 English
6-K,SECURITIES PURCHASE AGREEMENT
Regulatory Filings
2020-02-27 English
6-K,SECURITIES PURCHASE AGREEMENT
Report Publication Announcement
2020-02-27 English
Prospectus Supplement to Prospectus dated June 21, 2019
Capital/Financing Update
2020-02-26 English
Prospectus Supplement to Prospectus dated June 21, 2019
Report Publication Announcement
2020-02-26 English
Announces $8.0 Million Registered Direct Offering
Capital/Financing Update
2020-02-25 English
Announces $8.0 Million Registered Direct Offering
Report Publication Announcement
2020-02-25 English
Plan for Increased Production Capacity of AllocetraTM in Preparation for Potential Treatment of Coronavirus (COVID-19) Patients with Organ Failure
Regulatory Filings
2020-02-24 English
Plan for Increased Production Capacity of AllocetraTM in Preparation for Potential Treatment of Coronavirus (COVID-19) Patients with Organ Failure
Report Publication Announcement
2020-02-24 English
AMENDMENT NO. 2 TO FORM 20-F
Annual Report FY 2018
2020-02-01 English
AMENDMENT NO. 2 TO FORM 20-F
Regulatory Filings
2020-02-01 English
20F-Amendment No. 1
Annual Report FY 2018
2020-01-24 English
20F-Amendment No. 1
Report Publication Announcement
2020-01-24 English